Junker K - Search Results

1

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.

Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, Berdel WE, Thomas M. Broermann P, et al. Among authors: junker k. Cancer. 2002 Apr 1;94(7):2055-62. doi: 10.1002/cncr.10387. Cancer. 2002. PMID: 11932909 Free article.

2

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.

Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM. Junker K, et al. J Cancer Res Clin Oncol. 1997;123(9):469-77. doi: 10.1007/BF01192200. J Cancer Res Clin Oncol. 1997. PMID: 9341895 Clinical Trial.

3

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu.

Thomas M, Rübe C, Semik M, von Eiff M, Klinke F, Macha HN, Freitag L, Scheld HH, Willich N, Berdel WE, Junker K. Thomas M, et al. Among authors: junker k. Eur Respir J. 1999 Feb;13(2):424-9. doi: 10.1183/09031936.99.13242499. Eur Respir J. 1999. PMID: 10065692 Free article.

4

HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.

Junker K, Stachetzki U, Rademacher D, Linder A, Macha HN, Heinecke A, Müller KM, Thomas M. Junker K, et al. Lung Cancer. 2005 Apr;48(1):59-67. doi: 10.1016/j.lungcan.2004.10.010. Epub 2004 Dec 13. Lung Cancer. 2005. PMID: 15777971 Clinical Trial.

5

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.

Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, Willich N, Hamm M, Sybrecht GW, Ukena D, Deppermann KM, Dröge C, Riesenbeck D, Heinecke A, Sauerland C, Junker K, Berdel WE, Semik M; German Lung Cancer Cooperative Group. Thomas M, et al. Among authors: junker k. Lancet Oncol. 2008 Jul;9(7):636-48. doi: 10.1016/S1470-2045(08)70156-6. Epub 2008 Jun 24. Lancet Oncol. 2008. PMID: 18583190 Clinical Trial.

6

Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer.

Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W, Klinke F, Scheld HH, Willich N, Berdel WE, Junker K. Thomas M, et al. Among authors: junker k. J Clin Oncol. 1999 Apr;17(4):1185. doi: 10.1200/JCO.1999.17.4.1185. J Clin Oncol. 1999. PMID: 10561177 Clinical Trial.

7

p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy.

Junker K, Wiethege T, Müller KM, Thomas M. Junker K, et al. J Cancer Res Clin Oncol. 2000 Apr;126(4):238-45. doi: 10.1007/s004320050039. J Cancer Res Clin Oncol. 2000. PMID: 10782898

8

Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer.

Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, Scheld HH, Semik M. Reinmuth N, et al. Among authors: junker k. Eur Respir J. 2000 Nov;16(5):991-6. doi: 10.1183/09031936.00.16599100. Eur Respir J. 2000. PMID: 11153605 Free article.

9

Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.

Junker K, Langner K, Klinke F, Bosse U, Thomas M. Junker K, et al. Chest. 2001 Nov;120(5):1584-91. doi: 10.1378/chest.120.5.1584. Chest. 2001. PMID: 11713138 Clinical Trial.

10

[Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of "mediastinal downstaging"].

Langner K, Thomas M, Klinke F, Bosse U, Heinecke A, Müller KM, Junker K. Langner K, et al. Among authors: junker k. Chirurg. 2003 Jan;74(1):42-8; discussion 49. doi: 10.1007/s00104-002-0549-7. Chirurg. 2003. PMID: 12552404 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

475 results

Search Page

Filters